Navigation Links
High potency statins linked to better outcome following a heart attack
Date:2/20/2014

A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment with high-potency statins offers a significantly improved chance of survival compared to those taking normal statins.

The study, led by the University of Dundee, also found a combination of statins and the drug ezetimibe showed no improved survival rate, although researchers caution this finding needs further testing.

"There is presently a lot of interest in ezetimibe as a potential treatment for heart patients," said Professor Chim Lang, from the Division of Cardiovascular and Diabetes Medicine at the University of Dundee Medical School.

"Ezetimibe has been shown to be very effective at lowering cholesterol but we do not know its effect on survival. The key question really is whether it is better than statins, especially high potency statins such as rosuvastatin or atorvastatin.

"What our study has showed, looking at the data from thousands of patients in the UK, is that patients who switched from normal statin treatment to high potency statins lived longer.

"Those who had ezetimibe added did not appear to have a better outcome. So for the moment the data supports the use of high potency statins, one of which, atorvastatin, is now off patent and is cheap and effective."

Results of the study have been published online in the journal Heart.

Data for the study was drawn from the UK's Clinical Practice Research Datalink. Researchers looked at the data for patients who had survived 30 days after their first heart attack, who had not received prior statin or ezetimibe therapy, and who were started on a statin within that period of their attack.

The data of 9597 patients was used. 6990 of those were treated with simvastatin, 1883 had switched to a more potent statin, and 724 were given an ezetimibe/statin combination.

Data for the group was analysed for an average 3.2 years from the start point of their first heart attack. During that time there were 1134 deaths.

The results showed that patients who switched to a high-potency statin had a 28% lower risk of death compared to those who received simvastatin. There was no observed benefit of adding ezetimibe.


'/>"/>

Contact: Roddy Isles
r.isles@dundee.ac.uk
44-138-238-4910
University of Dundee
Source:Eurekalert

Related medicine news :

1. Sleep affects potency of vaccines
2. High-Potency Pot in Pregnancy May Cause Brain Damage
3. ReNew Life Launches Norwegian Gold EPA 1000 Omega, the Highest Potency EPA-only Fish Oil Supplement Sold in Health Food Stores
4. Ganetespib shows potency against ALK-positive lung cancer and overcomes crizotinib resistance
5. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces Prescription hCG Drops with Equal Potency to hCG Injections
6. ReNew Life, America’s #1 Probiotic Brand, Introduces a High-Potency Probiotic Uniquely Formulated for Women
7. ReNew Life, America’s #1 Probiotic Brand, Introduces a High-Potency Probiotic Uniquely Formulated for Women
8. Is There a Dark Side to High Potency Calcium? Source Naturals MBP Bone Renew Helps Consumers Avoid Potential Risks
9. Statins prevent cancer in heart transplant recipients
10. Statins May Help Prevent Enlarged Prostate: Study
11. Are Statins Less Helpful for Women?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Halfway through its partnership with First 5 LA, Western University of Health ... children 5 years old and younger and treatment services to more than 9,100 of ... years to Western University of Health Sciences, UCLA and USC, beginning March 1, 2013, ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... 02, 2016 , ... Center for Autism and Related Disorders (CARD) Portland today ... spectrum disorder (ASD) and other developmental disabilities. The group, which is being launched with ... caregivers the opportunity to share stories and advice, seek help, and continue their education ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet’s newest campaign, “Digestive Heath,” hits ... proof that attitude and determination can combine into the most remarkable achievements. Over ... holidays. This campaign will offer patients a new-found hope, by seizing the opportunity ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a class-leading provider of ... Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of ... new version is a faster and a more efficient product, allowing batch processing ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016 Research and Markets has announced ... Growth and Demand Forecast to 2022" report to their offering. ... , , ... in 2015, and it is expected to grow at a CAGR of ... to witness faster growth during the forecast period, a CAGR of 8.8% ...
(Date:12/2/2016)... Dec. 2, 2016 In the first ever ... from those derived from C. sativa, the Hebrew University ... di Napoli Federico II , the Universita` del Piemonte ... comprehensive, critical, integrated and unified inventory of phytocannabinoids of ... focuses on the remarkable chemical and structural diversity of ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, ... of Pharmaceutical Specialties, Inc. ("PSI").  The combination of ... Georgia -based PSI bring together both company,s clinical ... manufacturers, and payers an industry-leading specialty pharmacy. About ... , , ...
Breaking Medicine Technology: